Navigation Links
Steroids Provide No Survival Benefit for Children With Bacterial Meningitis
Date:5/6/2008

-Large Study Shows Benefits Differ from those in Adults-

PHILADELPHIA, May 6 /PRNewswire-USNewswire/ -- Corticosteroids given to children who are hospitalized for bacterial meningitis do not provide a benefit in survival or in reduced hospital stays, according to a large multicenter study by pediatric researchers. This finding stands in contrast to previous studies in hospitalized adults, for whom corticosteroids dramatically reduced mortality.

"Because of the demonstrated benefits of these drugs in adults, physicians have increasingly been using corticosteroids in children with bacterial meningitis," said study leader Samir S. Shah, M.D., an infectious diseases specialist from The Children's Hospital of Philadelphia. "This study reminds us again that children are not just small adults. We need to consider whether the problems associated with corticosteroid use, such as gastrointestinal bleeding, outweigh any potential benefits."

He added that further research should analyze whether corticosteroids may provide other benefits to children, such as improved neurological outcomes among survivors, a question not considered in this study.

The study appears in the May 7 issue of the Journal of the American Medical Association.

Shah's team analyzed medical records of 2,780 children with bacterial meningitis at 27 U.S. pediatric hospitals from 2001 to 2006. The median age of the children was nine months. Approximately 9 percent, or 248, of the children studied received corticosteroids, with steroid use doubling during the study period, from under 6 percent of children in 2001 to 12 percent in 2006.

There was no significant difference in mortality nor in time to hospital discharge, between children who received corticosteroids and those who did not. Overall, unadjusted mortality rates were 6 percent among children receiving corticosteroids, versus 4 percent among those not receiving them. There also was no significant difference in those outcomes between those receiving and not receiving corticosteroids in the subsets of children with meningitis caused by pneumococcal bacteria or by meningococcal bacteria.

Meningitis is an inflammation of the meninges, the membrane lining the brain. The bacterial form is relatively rare in children, with an incidence of about eight in 100,000 in the U.S. However, bacterial meningitis is potentially life-threatening, and requires hospitalization and treatment with antibiotics. Several different varieties of bacteria may cause meningitis, although the patterns have changed with the introduction of vaccines.

Previous studies had shown that corticosteroids had a clear benefit in preventing hearing loss in children whose meningitis was caused by Hemophilus influenzae type b (Hib) bacteria. However, since the Hib vaccine was approved for routine use in childhood immunizations in 1985, cases of Hib meningitis have dropped sharply in the United States. Now bacterial meningitis in children is more commonly caused by pneumococcal or meningococcal bacteria.

Further studies may reveal that corticosteroids may also reduce hearing loss or other neurologic injuries in children with bacterial meningitis not caused by Hib, said Shah, but there is currently no such evidence. He added, "Our study shows the need for a further study in children -- a large randomized clinical trial to examine all outcomes of steroid use, before the use of these medicines becomes routine in children with bacterial meningitis."

The National Center for Research Resources, part of the National Institutes of Health, supported the study, along with the Agency for Healthcare Research and Quality. One co-author, Jillian Mongelluzzo, received support from the Doris Duke Medical Student Clinical Research Fellowship. Shah's other co-authors were Zeinab Mohamad, M.S., from Children's Hospital, and Thomas R. Ten Have, Ph.D., from the University of Pennsylvania School of Medicine.

About The Children's Hospital of Philadelphia: The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking third in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 430-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu.

Contact: Rachel Salis-Silverman

Phone: (267) 426-6063

Salis@email.chop.edu


'/>"/>
SOURCE The Children's Hospital of Philadelphia
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
2. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
3. Gene Therapy Provides Vision to People who Were Nearly Blind
4. Arpida Provides Further Comments on the Pivotal Phase III Trials
5. Clinsys(R) TPS Teams Provide Comprehensive Clinical Development Plans
6. Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology
7. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
8. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
9. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
10. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
11. Stem Cell Research Provides Medical Breakthrough to Repair Heart Cell Damage Created by a Heart Attack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016  In the next ten ... shift from systems dependent on CRTs monitors to those ... modality CRT Medical monitors and will automatically sync ... host of foreseeable benefits to this technological advancement, ... modalities have to be replaced in order to ...
(Date:4/29/2016)... 29, 2016 Glycotope GmbH, a ... announces the appointment of Dr. Alfredo Zurlo ... an oncologist with many years clinical experience and a ... His last role was at Mologen AG where he ... Board. Previously Dr. Zurlo held various positions at F ...
(Date:4/28/2016)... April 28, 2016 Research and ... Plastic Surgery Products Market 2016-2020" report to their ... , The global plastic surgery products market ... during the period 2016-2020. , ,The growing adoption of ... the growth of the market. Lasers are used to ...
Breaking Medicine Technology:
(Date:5/3/2016)... Monica, CA (PRWEB) , ... May 03, 2016 , ... ... the highest quality medical providers to build the leading network of doctors and therapists ... Eric Nepomnaschy, D.C., founder of the distinguished Bay Chiropractic and Rehabilitation in ...
(Date:5/3/2016)... ... May 03, 2016 , ... SELEX (systematic evolution ... from a random library of sequences depending on their attraction for a target ... SELEX selection is commonly performed using filters, panning, or affinity chromatography separations. However, ...
(Date:5/3/2016)... FL (PRWEB) , ... May 03, 2016 , ... ... leading innovative specialty pharmacies, will be represented at the 2016 Asembia Specialty ... Vegas. The Asembia Summit is the largest U.S. health care conference for the ...
(Date:5/3/2016)... ... May 03, 2016 , ... Boston Children’s Hospital today announced its ... situations or practice tricky or rare procedures in an environment that looks and feels ... is also available to inventors and “hackers” to develop and test new devices or ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... announces Benefits Alliance Insurance Services as the latest addition to its elite stable ... comprised of Partners Wayne Blasman, David Styles, and Paul Vincent. The Firm is ...
Breaking Medicine News(10 mins):